Structural and functional consequences of the STAT5BN642Hdriver mutation.
de Araujo, E.D., Erdogan, F., Neubauer, H.A., Meneksedag-Erol, D., Manaswiyoungkul, P., Eram, M.S., Seo, H.S., Qadree, A.K., Israelian, J., Orlova, A., Suske, T., Pham, H.T.T., Boersma, A., Tangermann, S., Kenner, L., Rulicke, T., Dong, A., Ravichandran, M., Brown, P.J., Audette, G.F., Rauscher, S., Dhe-Paganon, S., Moriggl, R., Gunning, P.T.(2019) Nat Commun 10: 2517-2517
- PubMed: 31175292 
- DOI: 10.1038/s41467-019-10422-7
- Primary Citation of Related Structures:  
6MBW, 6MBZ - PubMed Abstract: 
Hyper-activated STAT5B variants are high value oncology targets for pharmacologic intervention. STAT5B N642H , a frequently-occurring oncogenic driver mutation, promotes aggressive T-cell leukemia/lymphoma in patient carriers, although the molecular origins remain unclear ...